75 Sidney Street
About Novartis Vaccines
Novartis Vaccines is a division of Novartis focused on the development of preventive treatments and is the world’s fifth-largest manufacturer and second-largest supplier of flu vaccines in the United States.
Novartis Vaccines is leading new innovation in vaccines research and manufacturing to protect health in areas of unmet medical need. The company has built a new manufacturing facility in Holly Springs, North Carolina. The state-of-the-art plant has been designed to provide 150 million adjuvanted doses of pandemic influenza vaccine within six months of declaration of an influenza pandemic.
Cell culture-derived influenza vaccines production represents the first major advancement in flu vaccine manufacturing in 50 years. Its advantages include greater speed, reliability, and flexibility in the vaccine manufacturing process.
Opportunities in Holly Springs
Novartis Vaccines has a range of opportunities in Holly Springs – from entry level to experienced, including scientists, technicians, laboratory personnel, engineers, and managers. Those who pursue their careers at the Holly Springs facility will be instrumental in meeting growing patient demand for seasonal influenza vaccines and in helping governments prepare for a possible flu pandemic. When fully operational, the Holly Springs site will provide 350 highly skilled jobs.
Novartis in Holly Springs has constructed a $36 million TD viral development lab and pilot plant. Construction is expected to be completed in early 2012.
Advancing Careers at Novartis
In order to establish itself as “an employer of choice,” Novartis has built a culture that empowers everyone to achieve technical and operational excellence with a focus on quality, safety, and customer service. The culture promotes high initiative, teamwork, mutual respect, collaboration and commitment to excellence. Novartis has been successful in attracting, retaining, and motivating employees by hiring the right people to fit the culture.
Novartis believes that its own success is directly tied to the success of its employees. Therefore, the company strives to be the best in business performance, scientific achievement, and the quality of its workplace. Novartis is proud to have been recently named the most admired pharmaceutical company in the world by Fortune, as well as on the “World’s Most Innovative Companies” list by Fast Company Magazine.
21 articles with Novartis Vaccines
Microbix Biosystems Inc. Sues Novartis Vaccines and Diagnostics For Infringement Of Its VIRUSMAX® Patent
Trimeris, Inc. and Roche Paying More Than $2.4 Million to Settle Fuzeon Patent Dispute With Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Begins Shipment of Seasonal Influenza Vaccine Fluvirin(R) to U.S. Market to Help Protect Ahead of 2010-2011 Flu Season
FDA Accepts Novartis Vaccines & Diagnostics, Inc.'s sBLA to Expand Indication of Menveo(R) to Children 2-10 Years of Age
BioMimetic Therapeutics, Inc. Strengthens its Agreement with Novartis Vaccines & Diagnostics, Inc. for Exclusive Supply of rhPDGF-BB
XOMA Ltd. Restructures Drug Development Collaboration with Novartis Vaccines & Diagnostics, Inc. Including Oncology Drug Candidate HCD122
FDA Approves 2008-2009 Season's Flu Vaccines: CSL Limited, Afluria. GlaxoSmithKline Biologicals, Fluarix. ID Biomedical Corporation of Quebec, FluLaval. MedImmune Vaccines, FluMist. Novartis Vaccines & Diagnostics, Inc., Fluvirin. Sanofi Pasteur, Fluzone.
Novartis Vaccines & Diagnostics, Inc. Signs Agreement With ProMetic BioSciences, Inc. To Develop An Affinity Ligand For Vaccine Purification
BioSpace, BayBio And Novartis Vaccines & Diagnostics, Inc. Unveil 2006-2007 Biotech Bay™ Hotbed Campaign
Novartis MeNZB(TM) Vaccine Campaign Data Show 80 Percent Efficacy Rate During Epidemic Meningococcal B Disease Outbreak In New Zealand
Novartis Vaccines And Diagnostics Awarded Up To USD 220 Million By U.S. Department Of Health And Human Services For Development Of Cell Culture-Derived Influenza Vaccine